• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2665-2665. ⟨10.1038/s41591-023-02624-w⟩. ⟨hal-04755672⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2024, 30 (7), pp.2089 - 2089. ⟨10.1038/s41591-024-03053-z⟩. ⟨hal-04753011⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Jérémie Calais, Agathe Edet-Sanson, Stephane Gaucher, Pierre Vera, Joseph Le Cloirec. Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting Candida albicans Tricuspid Endocarditis. The quarterly journal of nuclear medicine and molecular imaging, 2015, pp.1-8. ⟨10.1007/s13139-015-0333-5⟩. ⟨hal-01145000⟩
• 
  Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, et al.. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplantation, 2023, Bone Marrow Transplantation, 58 (5), pp.534-543. ⟨10.1038/s41409-023-01931-7⟩. ⟨hal-04672661⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Christian Borel, Xu-Shan Sun, Alexandre Coutte, Guillaume Bera, Christian Sire, et al.. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiotherapy & Oncology, 2024, 197, pp.110329. ⟨10.1016/j.radonc.2024.110329⟩. ⟨hal-04586362⟩
• 
  Loic Renaud, Juliette Wencel, Arnaud Pagès, Ahmad Al Jijakli, Hannah Moatti, et al.. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma. Haematologica, 2024, ⟨10.3324/haematol.2023.284689⟩. ⟨inserm-04671855⟩
• 
  A. Le Cesne, J. Y. Blay, D. Cupissol, A. Italiano, C. Delcambre, et al.. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Annals of Oncology, 2021, Annals of Oncology, 32 (8), p. 1034-1044. ⟨10.1016/j.annonc.2021.04.014⟩. ⟨hal-04522981⟩
• 
  Gilles Crochet, Gloria Iacoboni, Audrey Couturier, Emmanuel Bachy, Josu Iraola-Truchuelo, et al.. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.. Blood, 2024, ⟨10.1182/blood.2024024526⟩. ⟨hal-04607118⟩
• 
  Cédric Rossi, Marc André, Jehan Dupuis, Franck Morschhauser, Bertrand Joly, et al.. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.. Haematologica, 2022, Haematologica, 107 (12), pp.2897-2904. ⟨10.3324/haematol.2021.280004⟩. ⟨hal-04609851⟩
• 
  Marie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, Olivier Rigal, Johan Le Fel, et al.. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI: Journal of the National Cancer Institute, 2022, 115 (3), pp.322-331. ⟨10.1093/jnci/djac240⟩. ⟨hal-03992251⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
• 
  C. Thieblemont, B. Altmann, F. Frontzek, Loïc Renaud, L. Chartier, et al.. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis.. Blood Advances, 2023, BLOOD ADVANCES, 7 (15), p. 3968-3977. ⟨10.1182/bloodadvances.2022008888⟩. ⟨hal-04322322⟩
• 
  Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, Pierre Decazes, Alexandra Zduniak, et al.. High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock. Clinical Nutrition ESPEN, 2023, 55, pp.373-383. ⟨10.1016/j.clnesp.2023.04.007⟩. ⟨hal-04112173⟩
• 
  P. Kubicek, A. L. Cesne, C. Lervat, M. Toulmonde, C. Chevreau, et al.. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.. BMC Cancer, 2023, BMC Cancer, 23 (1), pp.69. ⟨10.1186/s12885-023-10556-4⟩. ⟨hal-04315885⟩
• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Pierre Decazes, Samy Ammari, Antoine de Prévia, Léo Mottay, Littisha Lawrance, et al.. Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs. Diagnostics, 2023, 13 (2), pp.205. ⟨10.3390/diagnostics13020205⟩. ⟨hal-04175332⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩

117

413